Sinopharm (CNCM) reports strong Q3 2025 revenue and profit growth

Sinopharm (CNCM LTD) recorded revenue of 13,747,350,727.81 yuan for the third quarter of 2025, a 3.58% increase over the same period last year. Net profit attributable to shareholders of the listed company rose by 13.10% to 543,717,921.74 yuan. Basic and diluted earnings per share also increased by 13.10% to 0.7206 yuan per share.

For the period from the beginning of the year to the end of the reporting period, total revenue reached 39,381,301,380.27 yuan, up 3.56% year-on-year. Net profit attributable to shareholders of the listed company for this nine-month period was 1,492,265,301.07 yuan, representing a 0.74% increase from the prior year.

As of September 30, 2025, total assets for Sinopharm (CNCM LTD) stood at 35,125,161,234.99 yuan, a 0.56% increase from the end of last year. Equity attributable to shareholders of the listed company grew by 5.34% to 18,042,614,851.34 yuan.